Company: LHI
Filing Date: 2025-08-08
Form Type: F-1/A
Source: 0001213900-25-073646
Chunk: 5

Company: Living Homeopathy International Ltd.
Filing Date: 2025-08-08
Form: F-1/A
Chunk 5
---
 and regulatory actions are new,
it is highly uncertain how soon the legislative or administrative regulation making bodies will respond and what existing or new laws
or regulations or detailed implementations and interpretations will be modified or promulgated, if any. In addition, due to long arm
provisions under the current laws and regulations of mainland China, there remains regulatory uncertainty with respect to whether in
the future we will be required to obtain permissions or approvals from the authorities of mainland China to operate our business or to
list our securities on the U.S. exchanges and offer securities.

The amended Cybersecurity
Review Measures, published by the Cyberspace Administration of China (the “CAC”) and 12 other relevant PRC government authorities
on December 28, 2021 and came into effect on February 15, 2022, provide that a “network platform operator” that possesses
personal information of more than one million users and seeks a listing in a foreign country must apply for a cybersecurity review. Further,
the relevant PRC governmental authorities may initiate a cybersecurity review against any company if they determine certain network products,
services or data processing activities of such company affect or may affect national security. As of the date of this prospectus,
subject to final determination by the CAC and relevant competent authorities, Han Kun Law Offices, our PRC counsel, has advised on
the basis that (i) our business operations are conducted in Hong Kong, (ii) we currently do not have or intend to set up any subsidiary
or VIE structure in mainland China, (ii) we do not have any business operations in mainland China, and (iii) we possess personal information
of less than one million individuals in the PRC and we have never been recognized as a critical information infrastructure operator in
the PRC, we are currently not required to obtain any permission or approval from the CAC or any other governmental authorities
of mainland China to operate our business or to list Living Homeopathy’s securities on the U.S. exchanges and offer securities,
nor have we been denied of any permissions or approvals from the authorities of mainland China.

Article 15 of the
Trial Administrative Measures of the Overseas Securities Offering and Listing by Domestic Companies, or the Overseas Listing Trial
Measures, promulgated by the China Securities Regulatory Commission (the “CSRC”) on February 17, 2023 and became
effective on March 31, 2023, provides that if the issuer meets the following criteria, the overseas securities offering and listing
con